Newer treatments target pathways like Delta-like ligand 3, poly-ADP-ribose polymerase, and histone deacetylase to address ...

A recent trial showed that nicotinamide riboside supplementation might reduce airway inflammation in patients with COPD who ...

We've all felt winded when taking the stairs or dealt with a cough from time to time. But if these issues linger, they could ...

Chronic obstructive pulmonary disease (COPD) and other lower respiratory diseases are among leading causes of U.S. deaths per ...

The global patient monitoring market size was valued at USD 55.60 billion in 2024 and is projected to reach from USD 59.66 billion in 2025 to USD 112.47 billion by 2033, growing at a CAGR of 7.3% ...

Explore strategies for controlling COPD and improving health, with a focus on management and lifestyle changes.

If these trials confirm the findings, benralizumab could become the first new therapy approved for eosinophilic exacerbations ...

The air we breathe. Time to act, innovate, and invest in solutions that will make every Indian breathe easy, live fully, and ...

If a threshold of 10% risk of COPD was used to make spirometry referrals, the addition of the polygenic risk score correctly ...

Tezepelumab did not significantly decrease moderate or severe COPD exacerbations compared with placebo, the COURSE trial found.